Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 26, 2025
Distillery Therapeutics

Inhibiting SLC13A3 for antitumor immunity

BioCentury | Dec 19, 2024
Product Development

Tertiary lymphoid structures: Key to predicting and improving cancer immunotherapy response?

At least two companies are preparing to take inducers of tertiary lymphoid structure into the clinic
BioCentury | Nov 7, 2024
Politics, Policy & Law

Probe intensifies spotlight on AstraZeneca in China

Global pharmas and local biotechs weigh fallout of investigation into AZ China head
BioCentury | Oct 19, 2024
Finance

Cash raises for Inventiva, Akeso, Capricor

Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on
BioCentury | Sep 18, 2024
Product Development

View from ESMO: iTeos data keep TIGIT alive, for now

Plus readouts from Genmab, AstraZeneca, Merck, Astellas and more
BioCentury | Aug 6, 2024
Deals

Deals Report: Bispecific space continues to foster partnerships

Plus: Otsuka in $800M takeout of Jnana, BioNTech dropping Genmab’s acasunlimab
BioCentury | Aug 3, 2024
Deals

Biotechs find problem-solving in academia, and mostly outside the big hubs 

Academia-biotech deals span innovative assets to tissue bank resources to enabling technologies
BioCentury | Jul 23, 2024
Product Development

Clinical Report: Ionis’ therapy for Angelman syndrome heading for Phase III

Plus: Data from Innovent, Agenus, Merck, Bayer and Orion
BioCentury | Jul 20, 2024
Product Development

Susan Galbraith: Five trends will drive the future of cancer treatment

Part 2 of an interview with AstraZeneca’s head of oncology
Items per page:
1 - 10 of 525